Chronic Graft-versus-host-diseasePhase 1/2NCT06843408
A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHD
A Phase 1/2 study testing INCA034176 in people with Chronic Graft-versus-host-disease, run by Incyte Corporation at 9 sites in China.
Trial summary
This study will be conducted to evaluate the safety, efficacy, and pharmacokinetics of axatilimab monotherapy in Chinese participants with recurrent or refractory active chronic graft-versus-host disease after systemic therapy. Read more about this study
- Who is it for?
- Ages 12 years and older
- Conditions the study is for
- Chronic Graft-versus-host-disease
- What is being tested?
- INCA034176
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 32 participants
- Where
- 9 sitesChina
- Study dates
- 25 Jun 2025to 20 Jul 2028
- Phase
- Phase 1/2
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 12 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- At least 12 years of age at the time of signing the ICF.
- Ability to comprehend and willingness to sign a written ICF for the study.
- For participants 12 to 17 years old: A parent/guardian must provide consent for pediatric participants; when applicable, pediatric participants should also sign an assent form.
- Chinese participants who are allo-HSCT recipients with active, refractory, or recurrent cGVHD requiring systemic immune suppression despite prior systemic therapy, including corticosteroids and at least 1 other appropriate treatment for refractory or recurrent cGVHD.
- Active cGVHD is defined as the presence of signs and symptoms of cGVHD per the 2014 NIH Consensus Development Project on Criteria for Clinical Trials in cGVHD (Jagasia et al 2015).
- Refractory disease is defined as meeting any of the following criteria:
Show all 25Show fewer
- The development of 1 or more new sites of disease while being treated for cGVHD.
- Progression of existing sites of disease despite at least 1 month of standard or investigational therapy for cGVHD.
- Participants who did not achieve a response within 3 months on prior therapy for cGVHD and for whom the treating physician believes a new systemic therapy is required.
- Recurrent cGVHD is defined as active, symptomatic disease (after an initial response to prior therapy) based on the NIH 2014 consensus criteria (Lee et al 2015) by organ-specific or global assessment or for which the physician believes a new line of systemic therapy is required.
- Participants may have persistent, active aGVHD and cGVHD manifestations (overlap syndrome), as defined by the 2014 NIH Consensus Development Project on Criteria for Clinical Trials in cGVHD.
- Karnofsky performance score of ≥ 60 (if aged 16 years or older); Lansky performance score of ≥ 60 (if aged younger than 16 years).
- Adequate organ and bone marrow functions evaluated during the 14 days prior to the start of study treatment as follows:
- Absolute neutrophil count ≥ 1.0 × 109/L (without growth factors within 1 week of study entry).
- Platelet count ≥ 50 × 109/L (without growth factor or transfusion within 2 weeks of study entry).
- ALT and AST ≤ 2.5 × ULN and total bilirubin ≤ 1.5 × ULN. Note: For participants with suspected or documented liver cGVHD: ALT and AST ≤ 5 × ULN and total bilirubin ≤ 1.5 × ULN.
- Creatinine clearance ≥ 30 mL/min/1.73 m2 based on the Cockcroft-Gault formula in adult participants and the Schwartz formula in pediatric participants.
- Concomitant use of a systemic corticosteroid is allowed but not required. Topical and inhaled corticosteroid agents are allowed. If a participant is taking a corticosteroid, it must be a stable dose for at least 2 weeks prior to the start of study treatment.
- Concomitant use of CNIs or mTOR inhibitors is allowed but not required (the inhibitor may have been started either for prophylaxis or for treatment of cGVHD; the reason for initiating treatment must be recorded in the database). If a participant is taking a CNI or an mTOR inhibitor, the following criteria must be met:
- Must be a stable dose for at least 2 weeks prior to the start of study treatment.
- The dose must be within the therapeutic range.
- Willingness to avoid pregnancy or fathering children based on the criteria below.
- Male participants with reproductive potential must agree to take appropriate precautions to avoid fathering children from screening through 90 days (a spermatogenesis cycle) after the last dose of study treatment and must refrain from donating sperm during this period. Permitted methods in preventing pregnancy should be communicated to the participants and their understanding confirmed.
- Female participants who are WOCBP must have a negative serum pregnancy test at screening and a negative urine pregnancy test before the first dose on Day 1 and must agree to take appropriate precautions to avoid pregnancy from screening through 30 days (1 menstrual cycle) after the last dose of study treatment and must refrain from donating oocytes during this period. Permitted methods in preventing pregnancy should be communicated to the participants and their understanding confirmed.
- Female participants not considered to be of childbearing potential as defined in the protocol are eligible.
Who cannot join
- Has aGVHD without manifestations of cGVHD.
- Any evidence (histologic, cytogenetic, molecular, hematologic, or mixed) of relapse of the underlying cancer or post-transplant lymphoproliferative disease at the time of screening.
- History of acute or chronic pancreatitis.
- Active symptomatic myositis.
- History or other evidence of severe illness, uncontrolled infection, allergy to excipients (see formulation details in the IB), or any other conditions that would make the participant, in the opinion of the investigator, unsuitable for the study.
- Positive HIV status.
Show all 17Show fewer
- History of latent or active TB, including either one of following:
- Signs or symptoms suggestive of active TB upon medical history and/or physical examination.
- Recent close contact with a person with active TB.
- Positive QuantiFERON and/or T-spot TB test at screening.
- Active HBV or HCV infection that requires treatment, or at risk for HBV reactivation (ie, positive HBsAg). Participants with negative HBsAg and positive total HBcAb and/or HBsAb should be excluded if quantitative HBV DNA test result is ≥ 20 IU/mL at the time of screening. Participants who are positive for HCV antibody are eligible only if PCR is negative for HCV RNA.
- Diagnosed with another malignancy (other than malignancy for which transplant was performed) within 3 years before Cycle 1 Day 1 unless previously treated with curative intent (eg, completely resected basal cell or squamous cell carcinoma of the skin, resected in situ cervical malignancy, resected breast ductal carcinoma in situ, or low-risk prostate cancer after curative resection) and approved by the sponsor's medical monitor.
- Pregnant or breastfeeding.
- Previous exposure to CSF-1R targeted therapies.
- Use of any agent other than corticosteroids, CNIs, or mTOR inhibitors for the treatment of cGVHD within 2 weeks or 5 half-lives, whichever is shorter, prior to the start of study treatment.
- Has received an investigational treatment within 28 days prior to the start of study treatment.
- Currently participating in any other interventional study.
Trial locations and contacts
9 sites in 1 country.
9 sites in 1 country
China9 sites
Peking University People'S Hospital
Beijing, 101149
West China Hospital of Sichuan University
Chengdu, 610041
The Second Affiliated Hospital, Army Medical University (Xinqiao Hospital)
Chongoing, 400037
Zhujiang Hospital of Southern Medical University
Guangzhou, 510280
Nanfang Hospital of Southern Medical University
Guangzhou, 510515
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, 310024
Shanghai Children'S Medical Center
Shanghai, 200127
Institute of Hematology, Chinese Academy of Medical Sciences
Tianjin, 301617
Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology
Wuhan, 430022
About this study
Official title: A Phase 1b/2, Open-Label, Multicenter Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory Active Chronic Graft-Versus-Host Disease After Systemic Therapy
This study will be conducted to evaluate the safety, efficacy, and pharmacokinetics of axatilimab monotherapy in Chinese participants with recurrent or refractory active chronic graft-versus-host disease after systemic therapy.
- Conditions
- Chronic Graft-versus-host-disease
- Being tested
- INCA034176
- Keywords
- cGVHD
- Medical subject headings
- Bronchiolitis Obliterans Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
INCA034176Drug
Also called Axatilimab
IV infusion
| Study group | Role | What they receive |
|---|---|---|
| Part 1 Safety Evaluation | Experimental | Axatilimab at the protocol-defined dose. Receives: Drug: INCA034176 |
| Part 2 Efficacy Evaluation | Experimental | Axatilimab at the protocol-defined dose. Receives: Drug: INCA034176 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of participants with Treatment-emergent Adverse Events (TEAEs)
Defined as adverse events reported for the first time or worsening of a pre-existing event, occurring after the first dose.
Measured: Up to 2 years and 30 days
Objective Response in the First 6 Cycles
The overall response rate will be assessed by the number of participants with objective response by Cycle 7 (28-day cycles), Day 1, with responses defined by the 2014 NIH Consensus Development Project on Criteria for Clinical Trials in cGVHD.
Measured: Up to Cycle 7 (Day 169)
Secondary outcomes (12)
Proportion of participants with a ≥ 7-point improvement in modified Lee symptom scale (mLSS) score
Measured: Up to 2 years
Overall Response Rate
Defined by the 2014 NIH Consensus Development Project on Criteria for Clinical Trials in cGVHD.
Measured: Up to 2 years
Duration of Response
Defined as the time from initial response of partial response or complete response until documented progression of cGVHD, start of new therapy, or death due to any cause, whichever occurs first.
Measured: Up to 2 years
Organ-specific Response Rate
Organ-specific response is defined as the number of participants with objective response for the nine individual organs based on 2014 NIH Consensus Development Project on Criteria for Clinical Trials in cGVHD (skin, eyes, mouth, esophagus, upper gastrointestinal [GI], lower GI, liver, lungs and joints and fascia).
Measured: Up to 2 years
Percent reduction in average daily dose (or equivalent) of corticosteroids
Measured: Up to 2 years
Proportion of participants who discontinue corticosteroid use
Measured: Up to 2 years
Percent reduction in average daily dose (or equivalent) of calcineurin inhibitors
Measured: Up to 2 years
Discontinuation of calcineurin inhibitor use after study entry.
Measured: Up to 2 years
Axatilimab pharmacokinetic (PK) in Plasma
Axatilimab concentration in plasma.
Measured: Up to 2 years and 30 days
Change from baseline in colony-stimulating factor-1 (CSF-1) and interleukin (IL)-34 levels and its association with cGVHD response.
Measured: Up to 2 years
Change from baseline in circulating monocyte number and phenotype (CD14/16).
Measured: Up to 2 years
Number of Participants with Anti-Drug Antibody (ADA)
Measured: Up to 2 years and 30 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Feb 2025
- Study start25 Jun 2025
- Primary completion6 Jan 2027 (estimated)
- Study completion20 Jul 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Chronic Graft-versus-host-diseaseStudies of the same condition, open and under way.
- More trials run by Incyte CorporationThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1/2
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 32 participants (actual)
Sponsor and investigators
- Lead sponsor
- Incyte Corporation
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Incyte Medical Monitor, Study director, Incyte Corporation
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06843408
- Sponsor's protocol ID
- INCA34176-204
- Status last verified
- Aug 2026
- First submitted
- 20 Feb 2025
- Last updated
- 10 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency